stella
beta
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus — Stella
Recruiting
Back to Chronic Kidney Disease (Stages 4 and 5) trials
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(1 site)
United States
Arizona Kidney Disease and Hypertension Center, Phoenix, Arizona
View full record on ClinicalTrials.gov